… Bivalent and quadrivalent human papillomavirus (HPV) vaccines are available that are
highly efficacious against persistent vaccine-type HPV infections and associated intraepithelial …

… This review discusses the future directions of therapeutic HPV vaccine approaches for the
… of HPV vaccine clinical trials. Table 3 lists the various therapeutic HPV vaccine clinical trials. …

… prophylactic vaccines. It will require larger clinical trials to confirm that the vaccine can …
the number of HPV types included in the vaccine to provide broad coverage. The durability …

… of clinical trial results for the two licensed prophylactic human papillomavirus (HPV) vaccines,
… It emphasizes the end of study analyses of the pivotal phase III trials in young women that …

… The Merck vaccine also includes types 6 and 11 covering ∼90% of genital warts. … vaccines
are in phase III clinical studies, and trial results available to date suggest that both vaccines …

… In addition, progression of therapeutic HPV vaccines through clinical trials may require
combination strategies employing different therapeutic modalities. As research in the …

… include women already exposed to vaccine HPV types. We … vaccine clinical trials evaluation
are likely to be slightly older (18–26 years old) than the full age range for whom the vaccine …

… age is before sexual exposure; administration of the vaccine to children has been … HPV
vaccines available to clinicians. Part I focuses on the debate over who should be vaccinated, at …

… HPV vaccines appear to induce sterilizing immunity from initial infection for a least a decade
… additional booster vaccination [1]. The high efficacy found in prelicensure clinical trials has …

… in receiving vaccines that prevented cervical … clinical trial that required shots and pelvic
examinations. A key motivating factor for clinical trial participation was the potential for a vaccine …